HK1080894A1 - Her-2/neu dna vaccine having anti-cancer activity - Google Patents

Her-2/neu dna vaccine having anti-cancer activity

Info

Publication number
HK1080894A1
HK1080894A1 HK06100716.7A HK06100716A HK1080894A1 HK 1080894 A1 HK1080894 A1 HK 1080894A1 HK 06100716 A HK06100716 A HK 06100716A HK 1080894 A1 HK1080894 A1 HK 1080894A1
Authority
HK
Hong Kong
Prior art keywords
dna vaccine
cancer activity
neu dna
neu
cancer
Prior art date
Application number
HK06100716.7A
Other languages
English (en)
Inventor
Joon Youb Lee
Dong-Hyeon Kim
Yeonseok Chung
Sun-Young Chang
Kyung-Chul Lee
Chang-Yuil Kang
Original Assignee
Viromed Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viromed Co Ltd filed Critical Viromed Co Ltd
Publication of HK1080894A1 publication Critical patent/HK1080894A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK06100716.7A 2002-07-16 2006-01-17 Her-2/neu dna vaccine having anti-cancer activity HK1080894A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20020041764 2002-07-16
KR1020030038012A KR100555211B1 (ko) 2002-07-16 2003-06-12 항암효과를 갖는 Ｈｅｒ-２/ｎｅｕ ＤＮＡ 백신
PCT/KR2003/001400 WO2004007734A1 (en) 2002-07-16 2003-07-15 Her-2/neu dna vaccine having anti-cancer activity

Publications (1)

Publication Number Publication Date
HK1080894A1 true HK1080894A1 (en) 2006-05-04

Family

ID=36126327

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06100716.7A HK1080894A1 (en) 2002-07-16 2006-01-17 Her-2/neu dna vaccine having anti-cancer activity

Country Status (8)

Country Link
US (2) US20060074038A1 (xx)
EP (1) EP1539971B1 (xx)
JP (1) JP4394570B2 (xx)
KR (1) KR100555211B1 (xx)
CN (1) CN100547075C (xx)
AU (1) AU2003281001A1 (xx)
HK (1) HK1080894A1 (xx)
WO (1) WO2004007734A1 (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100555211B1 (ko) * 2002-07-16 2006-03-03 주식회사 팬제노믹스 항암효과를 갖는 Ｈｅｒ-２/ｎｅｕ ＤＮＡ 백신
EP1649020B1 (en) * 2003-07-21 2017-01-11 MSD Italia S.r.l. Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof
ITMI20031942A1 (it) 2003-10-09 2005-04-10 Indena Spa Dna codificante p185^neu e suoi usi terapeutici
PT2162149E (pt) * 2007-06-01 2014-02-12 Jackson H M Found Military Med Vacina para a prevenção da recaída do cancro da mama
AU2008262391A1 (en) * 2007-06-06 2008-12-18 Avi Biopharma, Inc. Soluble HER2 and HER3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
JP5487410B2 (ja) 2010-02-22 2014-05-07 国立大学法人 岡山大学 生体硬組織接着用キット
US9056070B2 (en) 2010-04-27 2015-06-16 Universidad Manuela Beltran Autologous biological cancer vaccine
WO2011154863A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
US9956276B2 (en) 2012-01-19 2018-05-01 Duke University Vaccines against antigens involved in therapy resistance and methods of using same
KR101681597B1 (ko) 2014-01-17 2016-12-01 주식회사 바이오인프라 ANT2 siRNA를 함유하는 HER2 표적 항암제에 대한 내성 극복을 위한 조성물
US20170196953A1 (en) 2014-07-07 2017-07-13 Duke University VACCINES AGAINST AN ONCOGENIC ISOFORM OF HER2 (ErbB2) AND METHODS OF USING THE SAME
WO2016007504A1 (en) 2014-07-07 2016-01-14 Duke University Vaccines against an oncogenic isoform of esr1 and methods of using the same
US11253580B2 (en) 2016-01-07 2022-02-22 Duke University Cancer vaccines and methods of delivery
US11154597B2 (en) 2016-03-24 2021-10-26 Nantcell, Inc. Sequence arrangements and sequences for neoepitope presentation
JP7146732B2 (ja) 2016-07-13 2022-10-04 オハイオ ステート イノベーション ファウンデーション 宿主抗原提示並びに宿主抗腫瘍及び抗病原体免疫を最適化するためのプラットフォーム及び方法
US10487143B2 (en) 2016-10-05 2019-11-26 Duke University Vaccines against HER3 antigens and methods of using the same
US11224665B2 (en) 2016-10-05 2022-01-18 Duke University Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same
SG11201909882SA (en) 2017-04-24 2019-11-28 Nantcell Inc Targeted neoepitope vectors and methods therefor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0103976A3 (en) * 1998-10-05 2008-04-28 Pharmexa As Novel methods for therapeutic vaccination
ES2466715T3 (es) 1999-06-25 2014-06-11 Immunogen, Inc. Métodos de tratamiento usando conjugados de anticuerpo anti-ErbB-maitansinoide
KR100555211B1 (ko) 2002-07-16 2006-03-03 주식회사 팬제노믹스 항암효과를 갖는 Ｈｅｒ-２/ｎｅｕ ＤＮＡ 백신

Also Published As

Publication number Publication date
US20060074038A1 (en) 2006-04-06
AU2003281001A1 (en) 2004-02-02
WO2004007734A1 (en) 2004-01-22
KR20040007252A (ko) 2004-01-24
US8445268B2 (en) 2013-05-21
KR100555211B1 (ko) 2006-03-03
US20100210714A1 (en) 2010-08-19
JP2005533103A (ja) 2005-11-04
EP1539971A1 (en) 2005-06-15
JP4394570B2 (ja) 2010-01-06
EP1539971A4 (en) 2006-02-01
EP1539971B1 (en) 2014-04-16
CN100547075C (zh) 2009-10-07
CN1668750A (zh) 2005-09-14

Similar Documents

Publication Publication Date Title
HK1080894A1 (en) Her-2/neu dna vaccine having anti-cancer activity
AU2003247858A8 (en) Improved cannula system
AU2003272203A8 (en) Multiplex nucleic acid reactions
GB2386836B (en) Anti-cancer combinations
EP1682201A4 (en) LUER TYPE STAPLE
EP1670509A4 (en) MULTIPLEX VACCINES
GB0227081D0 (en) Methods for preparing catalysts
GB0225279D0 (en) Biological products
GB0224082D0 (en) Biological products
HUP0500013A3 (en) Infusion system
IL156816A0 (en) Stimulation arena
EP1660636A4 (en) VACCINES AGAINST CANCER
IL153346A0 (en) Vaccine against cancer diseases that are associated with the her-2/neu oncogene
AU2003269908A8 (en) Multiplex nucleic acid reactions
GB2409645B (en) Flower essence-containing medicaments
EP1446488A4 (en) REGULATED NUCLEIC ACID EXPRESSION SYSTEM
GB2395414B (en) Gel feed
PL377410A1 (pl) Leki przeciwko bólowi przewlekłemu
AU2003222378A8 (en) Combined dna vaccine and biological modifiers for cancer therapy
SI1670498T1 (sl) DNA, KI KODIRA p185 neu, IN TERAPEVTSKE UPORABE LE-TE
GB0215593D0 (en) New anticancer drugs
AU2002347346A8 (en) Dna vaccine
AU2002322013A1 (en) Therapeutic dna vaccination
GB0226717D0 (en) DNA vaccination
GB0208691D0 (en) Biological response modifiers

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20230714